Advertisement

Re: The correlation between PD-L1 expression and metabolic parameters of 18FDG PET/CT and the prognostic value of PD-L1 in non-small cell lung cancer

      Abstract

      We read with great interest the recent study conducted by Xu et al1. In this study, the authors investigated the correlation of programmed death ligand-1 (PD-L1) expression with metabolic parameters measured by 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG PET/CT) and its prognostic value in patients with surgically resected non-small-cell lung cancer (NSCLC). The results of this study1 found that in NSCLC patients, the maximum standardized uptake value (SUVmax) measured by 18F-FDG PET/CT was a predictor of PD-L1 expression, and both PD-L1 and TLG were prognostic factors for the prognosis of NSCLC patient. Undoubtedly, the novel findings of this study help to further refine the risk stratification of NSCLC patients. However, after reading this article carefully, we would like to share the following points.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Xu X.
        • Li J.
        • Yang Y.
        • et al.
        The correlation between PD-L1 expression and metabolic parameters of 18FDG PET/CT and the prognostic value of PD-L1 in non-small cell lung cancer.
        Clin Imaging. 2022 Jul; 2: 120-127
        • Samson P.
        • Patel A.
        • Garrett T.
        • et al.
        Effects of delayed surgical resection on short-term and long-term outcomes in clinical stage I non-small cell lung cancer.
        Ann Thorac Surg. 2015 Jun; 99 (discussion 1913): 1906-1912
        • Taylor M.D.
        • Nagji A.S.
        • Bhamidipati C.M.
        • et al.
        Tumor recurrence after complete resection for non-small cell lung cancer.
        Ann Thorac Surg. 2012 Jun; 93 (discussion 1820–1): 1813-1820
        • Osarogiagbon R.U.
        • Lin C.C.
        • Smeltzer M.P.
        • et al.
        Prevalence, prognostic implications, and survival modulators of incompletely resected non-small cell lung cancer in the U.S. National Cancer Data Base.
        J Thorac Oncol. 2016 Jan; 11: e5-e16
        • Adachi H.
        • Sakamaki K.
        • Nishii T.
        • et al.
        Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study.
        J Thorac Oncol. 2017 Jan; 12: 85-93
        • Burdett S.
        • Pignon J.P.
        • Tierney J.
        Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.
        Cochrane Database Syst Rev. 2015 Mar 2; CD011430